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Abstract
Background: Voluntary participation of a subject in research respects a subject’s rights, strengthens its ethical
conduct, and is formalized by the informed consent process. Clinical trials of life-saving interventions for medical
emergencies often necessitate enrolment of patients where prior written individual informed consent is impossible.
Although there are regulations and guidelines on protecting subjects in emergency research, these have been
criticised for being limited and unnecessarily restrictive. Across Europe and the United States stringent regulations
have resulted in a substantial decline of clinical trials involving emergency interventions.
Methods: We are conducting a trial of fluid resuscitation in children with hypovolaemic shock in six hospitals
across three malaria-endemic African countries. The design is pragmatic as children are enrolled on clinical criteria
alone and is being conducted in hospitals with facilities typical of many district hospitals across Africa. The trial
aims to inform strategy for managing children with febrile illness and features of shock. In order to develop
appropriate consent processes for the trial, we conducted a narrative review of current international
recommendations for emergency consent.
Results: Practical or specific guidance was generally sparse or confusing with few examples in the literature to
direct our informed consent process. For a sub-group of children who were critically sick or where parents
themselves were otherwise too distressed to consider prior written consent, we opted for a modified form of
deferred consent. This included verbal assent from guardians at the point of enrolment, with full written consent
obtained after stabilising the child. For children who died prior to full written consent, ethical permission was
received to waiver full consent.
Conclusions: In light of the controversy around guidance and regulations in this area we report how and why we
have used a modified system of deferred consent in an emergency intervention trial in children. Although
approved by all relevant ethics committees and operational in 3 countries in Africa, formal research is now
necessary to explore the perceptions and experiences of parents, health workers, researchers and ethics
committees of the modified method of deferred consent.
Background
Respect for persons, beneficence, and justice are the
principles underlying guidelines on the ethical conduct
of research in human subjects. The voluntary participa-
tion of a subject in a research study respects a subject’s
rights, and is formalized by the informed consent pro-
cess. In therapeutic studies and clinical trials in severely
ill children and emergency care the challenges for
researchers regarding fully informed consent are not tri-
vial. In these situations the requirements for the
protection of human subjects with diminished autonomy
presents unique and complex challenges. Although
seemly addressed by current international guidelines
and regulations, there are concerns that the recommen-
dations on the exceptions to informed consent, and the
interpretation of these by ethics committees, are too
restrictive [1-3]. As a consequence obtaining ethics
approval for resuscitation and emergency therapeutic
intervention trials is challenging, and trials of emergency
interventions are becoming increasingly uncommon
[4,5]. The major difficulty is how to approach informed
consent in research involving severely sick children in a * Correspondence: trudie.lang@ndm.ox.ac.uk
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acceptable to regulatory bodies and ethics committees.
Methods
Fluid Expansion As Supportive Therapy (FEAST) in cri-
tically ill African children trial is underway in six hospi-
tals across three African countries [6]. The trial
examines three different fluid resuscitation strategies on
48 hour and 28 day survival. The design is pragmatic as
children are enrolled on clinical criteria alone and it is
being conducted in hospitals with facilities typical of
many district hospitals across sub Saharan Africa. The
main objective of the trial is to facilitate clinicians and
policy makers working in sub-Saharan Africa in deciding
the best strategy to adopt in managing children with
febrile illness and features of shock.
For this late phase clinical trial of fluid resuscitation
http://feast-trial.org/ or ISCTRN 69856593 we con-
ducted a narrative review of international recommenda-
tions and guidelines, and of empirical literature, to
inform our process of consent. Following a detailed
review of international regulatory body requirements in
these settings, we searched the academic literature
through combining keywords in pubmed.org including
“emergency”, “consent”, “clinical trial”, “assent”, “waiver”,
“paediatric”, “community consultation “and “children”.
In particular, we considered two important practical and
ethical aspects of the consent process: community con-
sultation, and alternatives to prior full written consent
among populations with diminished autonomy. Informa-
tion from this review fed into consent discussions in
trial planning meetings.
Results
The Current International Regulatory Situation
The regulatory environment differs slightly between
Europe and the United States of America (US). The Eur-
opean clinical trial directive states that consent must be
given on behalf of a minor prior to research commencing
[7]. When this directive became law across Europe it
effectively resulted in a halt to emergency research in
children [8]. A few European countries have since
amended this law at national level to allow for emer-
gency research [9,10]. In the US, there was no provision
in their regulations that allowed any exception from the
informed consent requirement, for greater than minimal
risk emergency research. New regulations, brought in
1996, by the United States Food and Drug Administra-
tion (FDA)provided an opportunity for research to pro-
ceed without consent and designated such exemptions
from informed consent (EFIC) as “the Final Rule’’[11].
More than a decade later little progress has been made
in the study of therapies for acute, life-threatening con-
ditions with high mortality rates[12].
The key elements of the EFIC Final Rule include[13]:
1) the subject has an immediately life-threatening condi-
tion; 2) available treatments are unproven or unsatisfac-
tory; 3) consent from the subject (or a surrogate) is not
feasible due to the urgency of the patient/subject’sc o n -
dition; 4) the research could not otherwise be per-
formed; (5) the risks and benefits are reasonable; and (6)
there is a prospect that the trial will be of direct medical
benefit to the patient/subject. An additional requirement
is consultation with the community from which subjects
will be drawn, including public disclosure of the study
design and risks prior to commencement. As with all
research, it is also recommended that individual clinical
results are fed back continuously, and that research
findings are fed back when the study is over. Studies
have shown that the goals of the current regulatory
requirement, although well-conceived, were not being
met [14]. One example, highlighted was the ineffective-
ness of community consultation efforts.
Guidelines on emergency consent elsewhere in the
world vary or are not specifically addressed. For exam-
ple, South African Medical Research Council’sg u i d e -
lines make no specific recommendations for research in
emergency situations[15]. CIOMS Guidelines on Biome-
dical Research[3] and the UNESCO Declaration on Bio-
medicine[16] make clear that any waiver or delayed
consent should be a rare exception and subject to full
ethics committee review and must bring direct benefit
to the participant [3,8,16]. Others argue that it is often
not possible or appropriate to demonstrate benefit to
the individual [17]. The Australian authorities allow
emergency research if it is approved by the ethics com-
mittee as having an appropriate risk-benefit ratio, and if
there is no obvious reason why the participant would
refuse consent had they have been capable of consenting
[18]. In New Zealand the Health Research Council
require ethics committees to consider whether proposed
waived consent is appropriate given the research cir-
cumstances [19,20].
Approaching the Community
The FDA’s substantive requirement for community con-
sultation poses a significant challenge for emergency
research [21]. Problems include varying definitions of
what is meant by the term community for different stu-
dies[22,23], and lack of clarity in the aims and forms of
consultation. It is recognized that community consulta-
tion is not about obtaining community consent or endor-
sement of research, nor does it serve as a proxy for
consent or make an unethical study ethical. In some
cases community consultation is confused with commu-
nity information giving, or sensitisation. Although com-
munity consultation should provide investigators and
institutional review boards with insight into aspects of
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been considered by the investigators, exactly what should
be achieved with whom is a grey area. A workshop held
in 2006 which evaluated the issues and concerns around
the EFIC reached no consensus but called for more dis-
cussion and consideration of this question [24].
Community consultation and sensitisation activities
might best focus on those most likely to be recruited
into research, rather than general communities, many of
whom will not be eligible or involved in a hospital
based trial. A community consultation study by Morris
and colleagues sought the views of members of several
research communities (parents, healthcare workers)
regarding a hypothetical randomised controlled trial of
induced hypothermia in children [25]. Exception from
full prior informed consent was found to be acceptable,
but only if families were informed of the study prospec-
tively and had the opportunity to decline participation
of their child before enrolment.
Vulnerable populations
Vulnerable subjects in research generally include children,
prisoners, pregnant women, mentally disabled persons, or
economically or educationally disadvantaged persons [26].
These groups are recognised to both require special pro-
tection from abuse and exploitation and to be included
in research and associated benefits. In the setting of
resuscitation research, all potential subjects are vulnerable
by virtue of their lack of capacity to understand or com-
municate opinions regarding their participation in the
research. In the case of a child who requires resuscitation,
the accompanying parent or guardian acts as a surrogate.
However, adequately informed permission, even by a sur-
rogate decision-maker, is often impossible within the
short therapeutic window required for a successful inter-
vention (for example situations such as cardiac arrest, sta-
tus epilepticus or life-threatening shock). Moreover,
vulnerability in terms of difficulty in capacity to under-
stand or communicate opinions can extend to surrogate
decision makers in an emergency situation and under-
mines their ability to make an informed choice. In these
situations the requirement for informed and voluntary
parental permission may introduce a selection bias under-
mining the generalizability and feasibility of answering
specific research objectives. In the case of a paediatric
fluid resuscitation trial for the treatment of shock, the
requirement for full prior IC from all surrogates would
result in a trial conducted in a less critically ill cohort of
children whose data may be less informative or even mis-
leading for severely ill children.
The FEAST Trial and Deferred Consent
From our review of regulatory situation for different
regions and within the literature we found a lack of
detailed guidance or previous examples to follow that
were appropriate for this study. We were keen to ensure
the following:
1. There is written prior informed consent wherever
possible.Many, but importantly not all, of the chil-
dren that are eligible for the FEAST trial are severely
ill requiring emergency resuscitation and accompa-
nied by parents or guardians who may be too dis-
tressed to give fully informed consent. If a child is
stable enough to allow time and the parents or guar-
dians are not too distressed to understand the infor-
mation, ask questions and give or decline consent
then the standard consent process applies.
2. I n c o r p o r a t i o no fa no p t i o nf o rd e f e r r e dc o n s e n t
with prior assent.
For the trial to enrol, randomise and evaluate out-
comes of the three different fluid resuscitation stra-
tegies it was important that the design included
children across the severity range. We were con-
cerned that limiting the trial to children who were
not severely ill would result in potentially misleading
findings for the target group (the most unwell chil-
dren) as we would not obtained data from the chil-
dren who are at the most at risk. Furthermore,
excluding these children would then necessitate pro-
hibitively large and expensive trials of potentially
important therapeutic interventions as it would take
longer for a definitive answer to be derived. We con-
cluded that a process of deferred consent that incor-
porated verbal parental or guardian assent would
be appropriate for a sub-group meeting set criteria
(Figure 1). These criteria included surrogates who
appeared to be too distre s s e dt or e a da n du n d e r -
stand the information, ask questions and make an
informed decision. More commonly in this resource-
limited African setting many of surrogates are not
literate and thus require the full information sheets
read to them in the local language- which requires
sufficient time. Based on past research and practice
Degree of emergency Consent  status 
Pre-terminal Deferred consent 
Immediate resuscitation :other life 
threatening complications e.g. seizures, 
hypoglycaemia, hypoxia  
Deferred consent
No other life threatening complications: 
parent able to receive and understand 
information  
Full informed consent prior to enrolment
No other life threatening complications: 
guardian or parent not available or; parent 
or guardian unable to receive or understand 
information.
Deferred consent
Figure 1 Box 1 Criteria for deferred consent.
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consent process at enrolment was unlikely to result
in a ‘fully informed’ decision among highly distressed
surrogates; more likely to contribute to confusion
and concern.
Where deferred consent criteria were met, we were
guided by previous research on informed consent in
a rural African setting [27,28] and the findings of
the Morris study [25] described above. The provision
of basic awareness of the study in advance was one
of our requirements so this gave all parents/surro-
gates, regardless of the condition of their child or
the apparent levels of parental distress, an opportu-
nity to decline participation of their child before
enrolment. Parental or guardian ‘assent’ used in this
context is distinct from that given by a minor for
research, although it employs the same concept. The
information given during this verbal assent process
includes key elements of ICH-GCP (Figure 2). The
surrogate decision makers of potentially eligible chil-
dren are informed at admission that in addition to
standard care, their child may be involved in
research but not if they chose to opt out. Informa-
tion is conveyed by a short verbal ‘assent’ process,
and conducted at the point of enrolment by a spe-
cially trained study clinicians or nurses. Surrogates
could request fuller study information at this stage if
they wanted it. Verbal assent to the research, includ-
ing randomisation, is followed by the full details of
the study and request for formal written consent
only when the child’s medical condition has become
less critical.
Deferred consent therefore encompasses all required
details and relevant elements present in standard
consent, the difference being that the process is split
to give the minimum information verbally and fol-
lowed by full details later once logistically or justly
appropriate. Mostly importantly, the voluntary parti-
cipation in research is respected.
3. Early mortality - a challenge for deferred consent.
The a priori case fatality of the children eligible for
FEAST is high (over 15%[29]) and a proportion of
children enrolled following parental verbal assent die
before full informed consent is obtained. We gave
this predicted situation careful consideration. We
did not want to cause more distress to these parents,
yet these children’s data were fundamental to the
objectives of the trial, since early mortality is the pri-
mary endpoint. We opted not to approach parents
for retrospective full, written informed consent in
the event of death for three main reasons: a) parents
would have been through an assent process and
could request further trial information if they
required it as part of inevitable discussion after a
child’s death; b) revisiting the full consent process
might lead to parents blaming themselves for having
given permission to participate in research when it
would be difficult to explain retrospectively that fatal
outcome was not unexpected consequence of severe
illness; and c) the responsibility for ensuring overall
patient benefit from such a trial and appropriate
inclusion of children fell not with parents but with
the trial teams and ethics review committees.
4. Community consultation and sensitisation. For
this hospital based trial we discussed which commu-
nities to consult with and give information about the
trial. Drawing on the literature presented in this
paper, the focus of FEAST trial communication
strategy was aimed at hospital management team
and clinical and nursing staff, and to parents in the
paediatric wards. Trial specific information was not
circulated to chiefs and community leaders because
there were concerns that this would potentially con-
tribute to rumours and concerns, and more impor-
tantly because of the relatively small numbers of
patients involved (Kenya) and the difficulty in identi-
fying appropriate communities and representatives
(Tanzania and Uganda). As part of the process of
designing our community consultation and consent
methods, the trial incorporated ideas from a work-
shop involving independent paediatricians and ethi-
cists from the region (themselves representatives of
‘a form of community’).
5. Formal and Standardised Staff TrainingEssential
to the successful implementation of the above com-
munication and consent p r o c e s s e si st h a tF E A S T
trial staff receive specific informed consent training.
They are operationally assessed before and through-
out the study. A concern is that staff may opt for
verbal assent more than is strictly necessary, because
this is easier to do at the point of enrolment than
full prior written consent. We are therefore prospec-
tively recording reasons for its use in the trial data.
The process appears to be working well in practice,
and is being regularly monitored by the trial
1. We are going to provide the treatment for your child that is recommended by the 
government.
2. We want to find out if we can improve on these current recommendations by trying new 
treatments that we think will work better.  We do this by research.
3. All research is checked by independent committees to make sure that the potential benefits 
to individuals outweigh the risks.  All participation in research is voluntary, and so you can 
refuse.
4. We would like your child to participate in research for us to learn the best way to give fluids 
to very sick children.
5. Do you agree for your child to take part in this research? You can say no and your child will 
still receive the same level of care with the governments recommended treatment.
Figure 2 Box 2 Phrasing of assent in the deferred consent
process.
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ents are refusing trial enrolment either at point of
verbal assent or consent. This suggests that, at least,
some parents understand that they have a choice
and are exercising this right. If parents subsequently
decline written consent, which is usually when most
of the interventions have been completed, children
are withdrawn from the trial and the parents have
the right to choose whether or not to allow the use
of child’s trial data to be used for the primary end-
point (48-hour survival).
Discussion
Researchers and institutional review boards have ques-
tioned the interpretation and application of the 1996
Final Rule. They are concerned about whether research
in the chaotic environment of the emergency room, or
pre-hospital settings, provides participants with adequate
protection. Others believe that current regulations are
overprotective and restrictive, limiting important
research [4]. If the patient would trust the physician to
use unproven treatments as a routine therapy, then such
trust could be presumed to extend to using the same
treatment as part of a well designed and monitored
study which had been independently peer-reviewed and
endorsed by ethical approval.
By opting to use a process of deferred consent that
incorporates obtaining verbal assent the FEAST trial is
being conducted in accordance with the Nuffield Coun-
cil on Bioethics guidelines, and other international
guidelines [30,31]. It places more responsibility with the
ethics committees to decide whether they were confi-
dent that the rights and well being of the participants
are being protected. In East Africa there are no legal
requirements to follow particular guidelines, but
our institution works to ICH-GCP for all of our trials
http://www.kemri-wellcome.org. Whilst there are local
trial regulations to follow in each of the countries we
are working in, none gave specific details about emer-
gency research. The FEAST protocol, including the con-
sent processes described above, has obtained full ethical
approval in the UK and by three African committees.
Conclusions
We consider it of value to share how we approached
consent for this specific trial since severely ill children
are under-represented in research and current regula-
tions are challenging for researchers. The FEAST trial,
to our knowledge, is the first and the largest late phase
trial to have provided specific emergency consent pro-
cess since the change in regulatory requirements. How-
ever, we recognise that there now needs to be a formal
study to explore the views and experiences of different
groups involved, including parents, research staff, trial
monitors and managers, and members of ethics commit-
tees and regulatory agencies. In particular, we will be
interested in documenting these key stakeholders’ per-
ceptions of the acceptability and appropriateness of
deferred consent, and their recommendations for similar
studies in future.
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